The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationStahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1101 · Cited by 143
Kurrasch‐Orbaugh, D. M., Parrish, J. C., Watts, V. J., & Nichols, D. E. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01921.x · Cited by 138 · cited 4×
“…it has been shown that AA signaling probably involves G i/o and G 12/13, as well as G , Rho, mitogen-activated protein kinase kinase 1/2, and p38 MAPK (Kurrasch-Orbaugh et al., 2003a), indicating that more than one signaling cascade is responsible for 5-HT2A receptor-mediated AA release.”
BackgroundInfluentialSelf-citationDifferential phospholipase C activation by phenylalkylamine serotonin 5‐HT2Areceptor agonists
Parrish, J. C., Braden, M. R., Gundy, E., & Nichols, D. E. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03477.x · Cited by 41
Self-citation
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Self-citationAllosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Self-citationGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Structural Features for Functional Selectivity at Serotonin Receptors
Wacker, D., Wang, C., Katritch, V., Han, G. W., Huang, X.-P., Vardy, E., McCorvy, J. D., Jiang, Y., Chu, M., Siu, F. Y., et al. (2013) · Science · doi:10.1126/science.1232808 · Cited by 664
Self-citationCannabinoid Receptors: Where They are and What They do
Mackie, K. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01671.x · Cited by 638
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
“…theory and practice is the concept that the structure of a GPCR ligand may be systematically modified to confer alternative receptor conformations upon binding, with each displaying a unique pattern of activation of intracellular signaling cascades (Rankovic et al., 2016; Urban et al., 2007).”
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
Self-citationStructure, function and pathophysiology of protease activated receptors
Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., & Hooper, J. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.003 · Cited by 370
Melatonin receptors: role on sleep and circadian rhythm regulation
Dubocovich, M. L. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2007.10.007 · Cited by 364
Remote Control of Neuronal Signaling
Rogan, S. C., & Roth, B. L. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003020 · Cited by 339
Self-citationThe role of kinetic context in apparent biased agonism at GPCRs
Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328
Self-citationThird Generation Antipsychotic Drugs: Partial Agonism or Receptor Functional Selectivity?
Mailman, R., & Murthy, V. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361461 · Cited by 311
Self-citationAntipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Psychedelics as anti-inflammatory agents
Flanagan, T. W., & Nichols, C. D. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1481827 · Cited by 267
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
Community guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Gee, S., Ellwood, I., Patel, T., Luongo, F., Deisseroth, K., & Sohal, V. S. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5835-11.2012 · Cited by 214
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195
Barker, S. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00536 · Cited by 177
Psychedelic Drugs in Biomedicine
Kyzar, E. J., Nichols, C. D., Gainetdinov, R. R., Nichols, D. E., & Kalueff, A. V. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.08.003 · Cited by 155
Self-citationPsychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges
Chini, B., & Manning, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350737 · Cited by 123
Selective and potent agonists and antagonists for investigating the role of mouse oxytocin receptors
Busnelli, M., Bulgheroni, E., Manning, M., Kleinau, G., & Chini, B. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.202994 · Cited by 102
Discovery of new GPCR ligands to illuminate new biology
Roth, B. L., Irwin, J. J., & Shoichet, B. K. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2490 · Cited by 94
Self-citationArch, J. R. S. (2008) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-008-0271-1 · Cited by 96
Elucidation of G-protein and β-arrestin functional selectivity at the dopamine D2 receptor
Peterson, S. M., Pack, T. F., Wilkins, A. D., Urs, N. M., Urban, D. J., Bass, C. E., Lichtarge, O., & Caron, M. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502742112 · Cited by 91
Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71
Tadori, Y., Kitagawa, H., Forbes, R. A., McQuade, R. D., Stark, A., & Kikuchi, T. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.07.031 · Cited by 69
Baldinger, P., Kranz, G. S., Haeusler, D., Savli, M., Spies, M., Philippe, C., Hahn, A., Höflich, A., Wadsak, W., Mitterhauser, M., et al. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.002 · Cited by 67
CHINI, B., MANNING, M., & GUILLON, G. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00438-x · Cited by 65
Brust, T. F., Alongkronrusmee, D., Soto-Velasquez, M., Baldwin, T. A., Ye, Z., Dai, M., Dessauer, C. W., van Rijn, R. M., & Watts, V. J. (2017) · Science Signaling · doi:10.1126/scisignal.aah5381 · Cited by 64
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
Nuti, R., Gargaro, M., Matino, D., Dolciami, D., Grohmann, U., Puccetti, P., Fallarino, F., & Macchiarulo, A. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5005459 · Cited by 45
Association of histone modification with the development of schizophrenia
Chen, Y.-Z., Zhu, X.-M., Lv, P., Hou, X.-K., Pan, Y., Li, A., Du, Z., Xuan, J.-F., Guo, X., Xing, J.-X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116747 · Cited by 18
Full and partial agonism of a designed enzyme switch
Budiardjo, S. J., Licknack, T. J., Cory, M. B., Kapros, D., Roy, A., Lovell, S., Douglas, J., & Karanicolas, J. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00097 · Cited by 13
Metadata
- Authors
- Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., Miller, K. J., Spedding, M., & Mailman, R. B.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-01
- Volume
- 320
- Issue
- 1
- Pages
- 1-13
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2121473111
- Cited by
- 1,116
- References
- 4
- FWCI
- 28.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
